23.93
price down icon1.77%   -0.43
after-market 시간 외 거래: 23.94 0.01 +0.04%
loading
전일 마감가:
$24.36
열려 있는:
$21.62
하루 거래량:
2.29M
Relative Volume:
2.75
시가총액:
$1.97B
수익:
$352.57M
순이익/손실:
$-143.01M
주가수익비율:
-5.306
EPS:
-4.51
순현금흐름:
$-153.40M
1주 성능:
+7.94%
1개월 성능:
+2.22%
6개월 성능:
+3.46%
1년 성능:
-2.29%
1일 변동 폭
Value
$21.46
$24.79
1주일 범위
Value
$21.46
$24.95
52주 변동 폭
Value
$18.85
$49.50

빔 테라퓨틱스 Stock (BEAM) Company Profile

Name
명칭
Beam Therapeutics Inc
Name
전화
857-327-8775
Name
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
직원
461
Name
트위터
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
BEAM's Discussions on Twitter

빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-01-29 업그레이드 JP Morgan Neutral → Overweight
2023-12-15 다운그레이드 BofA Securities Buy → Neutral
2023-12-08 다운그레이드 Jefferies Buy → Hold
2023-10-20 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2023-10-20 다운그레이드 Leerink Partners Outperform → Market Perform
2023-03-21 개시 Bernstein Mkt Perform
2023-02-01 개시 Cantor Fitzgerald Overweight
2022-12-20 업그레이드 BMO Capital Markets Market Perform → Outperform
2022-12-13 개시 Citigroup Buy
2022-06-17 개시 BMO Capital Markets Market Perform
2022-04-28 개시 Credit Suisse Neutral
2022-01-05 개시 Guggenheim Buy
2021-10-19 개시 SVB Leerink Outperform
2021-09-24 재개 Stifel Buy
2021-09-10 개시 BofA Securities Buy
2021-05-11 개시 Redburn Buy
2021-05-04 개시 RBC Capital Mkts Sector Perform
2021-03-01 다운그레이드 Barclays Overweight → Equal Weight
2021-02-16 개시 Wells Fargo Overweight
2021-01-29 다운그레이드 JP Morgan Overweight → Neutral
2021-01-06 개시 Stifel Hold
2020-08-05 개시 William Blair Outperform
2020-03-02 개시 Barclays Overweight
2020-03-02 개시 JP Morgan Overweight
2020-03-02 개시 Jefferies Buy
2020-03-02 개시 Wedbush Outperform
모두보기

빔 테라퓨틱스 주식(BEAM)의 최신 뉴스

pulisher
05:24 AM

Beam Is Laser-Focused On ASH As It Reports Promising Sickle Cell Data, And A Death - Scrip

05:24 AM
pulisher
04:55 AM

SCD phase I/II death shines Beam on ‘very real’ busulfan risk - BioWorld Online

04:55 AM
pulisher
04:17 AM

Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results - MedCity News

04:17 AM
pulisher
03:37 AM

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial - Yahoo Finance

03:37 AM
pulisher
03:28 AM

JPMorgan maintains $48 target on Beam Therapeutics stock - Investing.com

03:28 AM
pulisher
03:28 AM

Stifel maintains $69 target on Beam Therapeutics stock - Investing.com

03:28 AM
pulisher
02:47 AM

Beam Therapeutics' early base editing clinical data overshadowed by patient death - The Business Journals

02:47 AM
pulisher
11:39 AM

Beam Therapeutics (NASDAQ:BEAM) Shares Gap Down Following Weak Earnings - MarketBeat

11:39 AM
pulisher
11:21 AM

Beam Therapeutics sustains Outperform stock rating on clinical data - Investing.com

11:21 AM
pulisher
10:55 AM

Beam Therapeutics (NASDAQ:BEAM) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat

10:55 AM
pulisher
10:32 AM

Beam Therapeutics sustains Outperform stock rating on clinical data By Investing.com - Investing.com UK

10:32 AM
pulisher
10:18 AM

Beam stock falls after fatality in gene editing trial - Seeking Alpha

10:18 AM
pulisher
09:23 AM

Sickle cell patient dies in Beam study of base editing therapy - BioPharma Dive

09:23 AM
pulisher
09:17 AM

Beam Therapeutics to Present Data Across Hematology - GlobeNewswire

09:17 AM
pulisher
09:00 AM

Beam Therapeutics' Sickle Cell Treatment Shows Promising Results in First Clinical Trial | BEAM Stock News - StockTitan

09:00 AM
pulisher
08:26 AM

Beam Therapeutics Inc Reports Q3 2024 EPS of $1.17, Revenue of $14.27 Million, Slightly Missing Estimates - GuruFocus.com

08:26 AM
pulisher
07:40 AM

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

07:40 AM
pulisher
07:30 AM

Beam Therapeutics Q3 24 Earnings Conference Call At 8:30 AM ET - Nasdaq

07:30 AM
pulisher
06:31 AM

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs - GlobeNewswire

06:31 AM
pulisher
02:44 AM

Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

02:44 AM
pulisher
Nov 04, 2024

Beam Therapeutics (NASDAQ:BEAM) Shares Up 6.5%Still a Buy? - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Beam Therapeutics (BEAM) Stock Surges with Strong Trading Volume - GuruFocus.com

Nov 04, 2024
pulisher
Nov 04, 2024

Beam Therapeutics's Earnings: A Preview - Benzinga

Nov 04, 2024
pulisher
Nov 01, 2024

Beam Therapeutics (BEAM) Stock Surges Amid Market Activity - GuruFocus.com

Nov 01, 2024
pulisher
Oct 31, 2024

Beam Therapeutics (BEAM): Promising Gene Editing Stock with Base Editing Technology - Insider Monkey

Oct 31, 2024
pulisher
Oct 31, 2024

(BEAM) Investment Analysis - Stock Traders Daily

Oct 31, 2024
pulisher
Oct 30, 2024

Beam Therapeutics (BEAM) Set to Announce Quarterly Earnings on Tuesday - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds - Insider Monkey

Oct 30, 2024
pulisher
Oct 30, 2024

64,313 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Bought by International Assets Investment Management LLC - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting - ForexTV.com

Oct 29, 2024
pulisher
Oct 29, 2024

Beam Therapeutics to Hold Conference Call to Discuss Third - GlobeNewswire

Oct 29, 2024
pulisher
Oct 29, 2024

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences - GlobeNewswire

Oct 29, 2024
pulisher
Oct 28, 2024

We're Interested To See How Beam Therapeutics (NASDAQ:BEAM) Uses Its Cash Hoard To Grow - Yahoo Finance

Oct 28, 2024
pulisher
Oct 28, 2024

Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price - Simply Wall St

Oct 28, 2024
pulisher
Oct 24, 2024

Beam Therapeutics' SWOT analysis: base editing biotech stock faces pivotal year By Investing.com - Investing.com South Africa

Oct 24, 2024
pulisher
Oct 23, 2024

Beam Therapeutics' SWOT analysis: base editing biotech stock faces pivotal year - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Beam Therapeutics (BEAM): A Small-Cap Leader in Precision Genetic Medicine - Yahoo Finance

Oct 23, 2024
pulisher
Oct 23, 2024

8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey

Oct 23, 2024
pulisher
Oct 20, 2024

(BEAM) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 20, 2024
pulisher
Oct 18, 2024

Beam Therapeutics (BEAM): The Next Frontier in Biotech - TipRanks

Oct 18, 2024
pulisher
Oct 17, 2024

State Street Corp's Strategic Acquisition in Beam Therapeutics Inc - Yahoo Finance

Oct 17, 2024
pulisher
Oct 17, 2024

Beam Therapeutics (NASDAQ:BEAM) Trading Down 6.6% After Insider Selling - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Scotiabank Initiates Coverage of Beam Therapeutics (BEAM) with Sector Perform Recommendation - Nasdaq

Oct 17, 2024
pulisher
Oct 17, 2024

Beam Therapeutics president sells $1.34 million in stock - Investing.com

Oct 17, 2024
pulisher
Oct 16, 2024

Beam Therapeutics president sells $1.34 million in stock By Investing.com - Investing.com South Africa

Oct 16, 2024
pulisher
Oct 16, 2024

Insider Selling: Beam Therapeutics Inc. (NASDAQ:BEAM) President Sells 51,110 Shares of Stock - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

BEAM Crosses Above Key Moving Average Level - Nasdaq

Oct 16, 2024
pulisher
Oct 16, 2024

Examining Beam Therapeutics Inc (BEAM) more closely is necessary - US Post News

Oct 16, 2024
pulisher
Oct 16, 2024

Beam Therapeutics (NASDAQ:BEAM) Earns Sector Outperform Rating from Analysts at Scotiabank - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Beam Therapeutics Inc [BEAM] Investment Guide: What You Need to Know - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

What is Beam Therapeutics Inc (BEAM) Stock Return on Shareholders’ Capital? - SETE News

Oct 15, 2024

빔 테라퓨틱스 (BEAM) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

빔 테라퓨틱스 주식 (BEAM) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Ciaramella Giuseppe
President
Oct 14 '24
Sale
26.27
51,110
1,342,752
160,260
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):